India

First successful transplant of HeartMate 3â„¢ conducted in India – LVADs soon to become popular among end-stage heart disease patients

Views: 6.0K
Dr Kewal Krishan, Program Head “ Heart Transplant and Ventricular Assist Devices and Senior Consultant Cardiac Surgeon at Max Super Specialty Hospital, Saket

Dr Kewal Krishan
Program Head “ Heart Transplant and Ventricular Assist Devices and Senior Consultant Cardiac Surgeon at Max Super Specialty Hospital, Saket

Internationally renowned Dr Kewal Krishan, Program Head “ Heart Transplant and Ventricular Assist Devices and Senior Consultant Cardiac Surgeon at Max Super Specialty Hospital, Saket, performed Indias first successful implant of HeartMate 3â„, which offers physicians the worlds most advanced ventricular assist technology available to support the management of patients with advanced stage heart failure.

Credentials

  • One of the handful surgeons in India to be formally trained in all aspects of heart transplantation.
  • An Advanced Clinical Fellow at the worlds top hospitals, including Mayo Clinic and Mount Sinai Medical Center, the United States (US)
  • Credited with the distinction of performing the maximum number of left ventricular assist devices (LVADs) in one year in India
  • Has performed the maximum number of extracorporeal membrane oxygenation (ECMO) in the country in patients with severe lung or heart condition.
  • Also performed the first heart transplant of Max Healthcare in India

Overview

HeartMate 3â„

HeartMate 3â„

The HeartMate 3â„ implant surgery was performed in early May 2016 on a 69-year-old gentleman from New Delhi, who had earlier undergone stenting twice in 2005 and 2009 and had been put on medical management for a triple vessel coronary artery disease, diabetes mellitus and end stage cardiomyopathy with ejection fraction (EF) 15%.

Besides implanting HeartMate 3â„, Dr Krishan also removed a clot from the right ventricle and repaired the aortic valve. HeartMate 3â„ LVAD implant was advised as destination therapy for symptomatic end-stage heart disease, since medical management was found to be insufficient for the patients condition.

Since the LVAD implant, the patients heart condition and quality of life have improved considerably and with immediate effect.

Why LVAD?

LVADs dont replace the heart, but supplement the pumping function in patients whose hearts are too weak to pump blood adequately on their own. They can be used in patients who are awaiting heart transplant, as well as patients who cannot undergo transplantation for any reason.

With the availability of HeartMate 3â„ system in India, advanced heart failure patients will no longer need to travel abroad to get this implant.

 

HeartMate 3â„ System “ Key Takeaways

An LVAD is a battery-operated mechanical pump, which helps the left ventricle “ the main pumping chamber of the heart “ to pump blood to the rest of the body.

More than 50,000 LVAD implants have been performed across the world.

  • A highly advanced fully magnetically levitated LVAD that reduces friction and provides blood-friendly wide pump gaps to reduce issues, such as blood stagnation and thrombus formation or clotting
  • Can pump up to 10 litres of blood per minute
  • The Full MagLevâ„system enables an artificial pulse every 2 seconds by rapidly changing rotor speeds while maintaining pump gaps, thereby ensuring washing of the impeller
  • Comes with a smaller sized pump to increase surgical ease to implant and enhances patients life expectancy significantly
  • Allows the patient to have an active life with limited caution, with immediate symptomatic relief and improvement in the left heart function
  • Equipped to work with GoGear wearable accessories
  • Has shown zero-rate of pump thrombosis and excellent patient outcomes, according to the one-year Food and Drug Administration (FDA) data
  • Has received CE Mark approval in October 2015, based on data from the clinical trial, which demonstrated a 92 percent six-month survival rate; the best six-month survival rate to date to be documented in an LVAD CE Mark clinical study

Most Popular

To Top